Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mild Insider Selling at PriceSmart Inc. (PSMT) and ANSYS Inc. (ANSS); Insider Buying at Three Other Companies

Board Member of Struggling Mistras Group Boosts Ownership Stake

A member of Mistras Group Inc. (NYSE:MG)’s Board of Directors also filed a Form 4 with the SEC on Thursday to disclose some security purchases. Nicholas DeBenedictis, a member of the seven-member Board of Directors at Mistras Group, reported the purchase of 2,500 shares on Thursday at $22.52 apiece and 2,500 shares on Wednesday for $22.75 each, all of which are held by his spouse, who currently owns an aggregate of 10,000 shares. Mr. DeBenedictis holds a direct ownership stake of 16,479 shares.

The insider buying comes shortly after the global provider of technology-enabled asset protection solutions released its financial results for the second quarter of its fiscal year 2017 earlier this year. Mistras Group Inc. (NYSE:MG)’s revenues for the three months that ended November 30 decreased by 9% year-over-year to $176.6 million. The decrease mainly reflects weak North American oil and gas market conditions, as well as the timing of customer project-related spending. Nonetheless, despite experiencing a decline in revenues, the company’s gross profit margins improved for the sixth consecutive quarter. Mistras Group’s shares are up 10% in the past year. Joel Greenblatt’s Gotham Asset Management added an 83,656-share position in Mistras Group Inc. (NYSE:MG) to its portfolio during the September quarter.

Follow Mistras Group Inc. (NYSE:MG)
Trade (NYSE:MG) Now!

CEO of Low-Priced Clinical-Stage RNAi Company Purchases Shares

The man at the helm of RXi Pharmaceuticals Corp (NASDAQ:RXII) purchased some shares on Thursday. President and CEO Geert Cauwenbergh bought 10,000 shares yesterday at a weighted average price of $0.695 per share. Dr. Cauwenbergh currently owns an aggregate of 62,583 shares after the Thursday purchase.

As the shares of the clinical-stage RNAi company have dropped by 79% in the past one year, the insider purchase discussed above represents a classical example of when corporate insiders step up and buy shares. The so-called RNAi therapies are designed to “silence” the expression of a specific gene that may be over-expressed in a disease condition. RXi Pharmaceuticals Corp (NASDAQ:RXII)’s clinical development programs include RXI-109, deigned for the treatment of dermal and ocular scarring, and Samcyprone, designed for the treatment of a series of disorders such as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Earlier this month, RXi Pharmaceuticals completed the acquisition of privately-held MirImmune Inc., a company that develops next generation immunotherapies for the treatment of cancer. Kevin Kotler’s Broadfin Capital LLC held 316,010 shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) at the end of the September.

Follow Phio Pharmaceuticals Corp. (NASDAQ:PHIO)
Trade (NASDAQ:PHIO) Now!

The final page of the article focuses on discussing fresh insider selling observed at two other companies.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.